journal
MENU ▼
Read by QxMD icon Read
search

Innovations in Clinical Neuroscience

journal
https://www.readbyqxmd.com/read/30254798/ethical-reflections-on-offering-patients-accelerated-resolution-therapy-art
#1
EDITORIAL
Edmund G Howe, Laney Rosenzweig, Amy Shuman
Accelerated resolution therapy (ART) is a new therapy for post-traumatic stress disorder (PTSD) that has shown exceptional promise. Compared with other standard, more evidence-based treatments, initial research has shown ART to be as effective, quicker, easier to learn, and more cost-efficient. There are ethical issues clinicians should consider before recommending ART to their patients, including the need for additional research to fully establish ART's net benefits and the difficulty patients might encounter accessing therapists trained to perform ART-based therapy...
July 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30254797/worsening-choreoathetosis-in-huntington-s-disease-with-fluoxetine-lisdexamfetamine-and-melatonin-a-case-report
#2
Clayton J Hamilton, Tysen K Timmer, Robert C Munjal, Fernando Cardozo-Pelaez, Ian R Mcgrane
Cognitive, affective, and sleep disturbances can be found in patients with Huntington's disease (HD), and medications used to treat these HD-related sequela can also impact HD-related movement disorders. We present the case of a 52-year-old Caucasian man with previously undiagnosed HD who exhibited significant choreoathetoid movements that improved with discontinuation of fluoxetine and lisdexamfetamine upon hospital admission. Following diagnosis of HD through genetic testing, he was administered 5mg of oral melatonin on two consecutive evenings, which resulted in worsening choreoathetosis...
July 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30254796/transition-from-obsession-to-delusion-in-schizo-obsessive-disorder-a-case-report-and-literature-overview
#3
Estêvão Scotti-Muzzi, Osvaldo Luis Saide
Schizo-obsessive disorder has been proposed to classify those who show schizophrenia and obsessive compulsive disorder (OCD) diagnoses. This subgroup has recently shown to be much more prevalent than previously thought, as well as presenting distinct clinical, phenomenological and neurobiological features from the parental diseases. We present a case report of a 32-year-old man who first manifested obsessive-compulsive symptoms (OCS) in his early twenties, followed by emergence of consistent negative schizophrenia symptoms, as well as intermittent aggressive behavior...
July 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30254795/atypical-neuroleptic-malignant-syndrome-precipitated-by-clozapine-and-quetiapine-overdose-a-diagnostic-challenge
#4
David Choon Liang Teo, Hon Khuan Wong, Sheng Neng Tan
Neuroleptic malignant syndrome (NMS) is a rare, idiosyncratic, but life-threatening adverse reaction associated with the use of antipsychotic drugs. It is characterized by a tetrad of fever, rigidity, autonomic instability, and altered mental status. Failure to diagnose NMS early and institute appropriate treatment can result in serious medical complications and death. While diagnostic criteria for NMS exist, atypical presentations that lack one or more characteristic features pose a diagnostic dilemma to clinicians...
July 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30254794/implementation-of-the-electronic-columbia-suicide-severity-rating-scale-ec-ssrs%C3%A2-across-four-phase-iiib-clinical-trials-in-hiv-infected-individuals-aria-striiving-dawning-and-inspiring
#5
Clare Brennan, Hannah Whillis, Choy Man, Brian Wynne, Vani Vannappagari
Objective : Increased rates of suicidal ideation/behavior have been reported in individuals with human immunodeficiency virus infection/acquired immunodeficiency syndrome. The electronic Columbia-Suicidality Severity Rating Scale (eC-SSRS™) is a validated tool for assessment of suicidal risk. The objective of this study was to assess the site perspectives on implementation of the eC-SSRS used in Phase IIIb studies of dolutegravir. Methods : We developed and validated the ViiV eC-SSRS Metrics and Perspectives Site Questionnaire (VEQ)...
July 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30254793/can-youtube-%C3%A2-disseminate-dementia-knowledge-to-singapore-chinese
#6
Benjamin K P Woo
No abstract text is available yet for this article.
July 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30254792/author-response
#7
Rajashekar Reddy Yeruva, Steven Lippmann
No abstract text is available yet for this article.
July 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30254791/regarding-zika-microcephaly
#8
Beuy Joob, Viroj Wiwanitkit
No abstract text is available yet for this article.
July 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30254790/metabolic-changes-in-patients-with-schizophrenia-switched-from-olanzapine-to-asenapine-or-clozapine
#9
Masaru Nakamura, Takahiko Nagamine
No abstract text is available yet for this article.
July 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30013819/atrial-fibrillation-and-injected-aripiprazole-a-case-report
#10
Anthi Stefatos, Julie N Ha, Adrian Baranchuk, Ross J Baldessarini, Gustavo H Vázquez
Background: Aripiprazole is a widely clinically employed antipsychotic drug for a range of indications. It has unusual pharmacodynamics as a dopamine D2 receptor partial-agonist with complex interactions with serotonin receptors and, a relatively unusual long elimination half-life. Although other atypical antipsychotics have been associated with an increased risk of atrial fibrillation, aripiprazole is considered to be relatively neutral in regard to its cardiac risk. We report a case of a 45-year-old Caucasian patient with schizoaffective disorder who developed acute atrial fibrillation (AF) several days after an intramuscular injection of a large long-acting dose of the drug after low oral doses had been well-tolerated...
June 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30013818/development-of-a-behavioral-health-stigma-measure-and-application-of-machine-learning-for-classification
#11
REVIEW
Farah Tokmic, Mirsad Hadzikadic, James R Cook, Oleg V Tcheremissine
Objective: Given the growing public health importance of measuring the change in mental health stigma over time, the goal of this study was to demonstrate the potential for using machine learning as a tool to analyze patterns of social stigma as a complement to traditional research methods. Methods: A total of 1,904 participants were recruited through Sona Systems, Ltd (Tallinn, Estonia), an experiment management system for online research, to complete a self-reported survey. The collected data were used to develop a new measure of mental (behavioral) health stigma...
June 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30013817/delirium-and-psychotic-symptoms-associated-with-hyperglycemia-in-a-patient-with-poorly-controlled-type-2-diabetes-mellitus
#12
Rui Lopes, Bernardo Dias Pereira
Delirium, acute confusional states, and secondary psychosis have been associated with several medical conditions, including endocrine disorders. In the context of diabetes mellitus (DM), it has been mostly related to hypoglycemia and rarely occurs in association with hyperglycemia, outside of the context of a hyperglycemic hyperosmolar state or diabetic ketoacidosis. Here, we describe a case of delirium and psychotic symptoms associated with hyperglycemia in a patient with poorly controlled Type 2 DM as an attempt to alert clinicians to this rare association...
June 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30013816/effects-of-lisdexamfetamine-dimesylate-on-functional-impairment-measured-on-the-sheehan-disability-scale-in-adults-with-moderate-to-severe-binge-eating-disorder-results-from-two-randomized-placebo-controlled-trials
#13
David V Sheehan, Maria Gasior, Susan L McElroy, Jana Radewonuk, Barry K Herman, James Hudson
Objective: In two Phase III, randomized, placebo-controlled trials (NCT01718483 and NCT01718509 at ClinicalTrials.gov), lisdexamfetamine dimesylate (LDX) reduced binge eating days/week in adults with moderate-to-severe binge eating disorder (BED). We describe the effects of LDX (50mg and 70mg) on the Sheehan Disability Scale (SDS; exploratory endpoint) from both studies. Design: The SDS was assessed at baseline, Week 6, and Week 12/early termination. Analyses included mixed-effects models for repeated measures for the examination of SDS total and domain score changes and a generalized estimating equation model to assess dichotomized remission status (remission [total score ≤6] versus nonremission [total score >6])...
June 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30013815/combination-phentermine-topiramate-extended-release-for-the-treatment-of-binge-eating-disorder-an-open-label-prospective-study
#14
Anna I Guerdjikova, Stephanie Williams, Thomas J Blom, Nicole Mori, Susan L McElroy
Objective: The goal of this study was to obtain preliminary data on the usefulness of the combination of phentermine and topiramate extended release (phentermine-topiramate) in binge-eating disorder (BED) associated with obesity or overweight. Design: Ten participants with BED and obesity or overweightness with at least one weight-related complication received phentermine-topiramate in an open-label, prospective, 12-week trial. The primary outcome measure was change in weight. The study was registered under the identifier NCT02659475 at ClinicalTrials...
June 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30013814/valbenazine-and-deutetrabenazine-for-tardive-dyskinesia
#15
REVIEW
Katie T B Touma, Jonathan R Scarff
Tardive dyskinesia (TD) is a medication-induced permanent movement disorder with no United States Food and Drug Administration (FDA)-approved treatments prior to 2017. Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or discontinuation due to a risk of psychiatric decompensation. Valbenazine and deutetrabenazine were recently approved by the FDA for the treatment of TD. They offer a unique mechanism of action by inhibiting vesicular monoamine transporter type 2...
June 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30013813/effective-pain-control-in-hutchinson-gilford-progeria-syndrome
#16
Muhammad Hassan Majeed, Muhammad Ubaidulhaq, William E Gusa
No abstract text is available yet for this article.
June 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/30013812/kratom-and-the-opioid-crisis
#17
Durga Bestha
No abstract text is available yet for this article.
June 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29721364/audio-recording-for-independent-confirmation-of-clinical-assessments-in-generalized-anxiety-disorder
#18
Steven D Targum, Christopher Murphy, Jibran Khan, Laura Zumpano, Mark Whitlock, Arthur A Simen, Brendon Binneman
Objective : The assessment of patients with generalized anxiety disorder (GAD) to deteremine whether a medication intervention is necessary is not always clear and might benefit from a second opinion. However, second opinions are time consuming, expensive, and not practical in most settings. We obtained independent, second opinion reviews of the primary clinician's assessment via audio-digital recording. Design : An audio-digital recording of key site-based assessments was used to generate site-independent "dual" reviews of the clinical presentation, symptom severity, and medication requirements of patients with GAD as part of the screening procedures for a clinical trial (ClinicalTrials...
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707426/is-electroconvulsive-therapy-a-treatment-for-depression-following-traumatic-brain-injury
#19
Anja Srienc, Puneet Narang, Simrat Sarai, Yee Xiong, Steven Lippmann
Traumatic brain injury (TBI) can be caused by blunt or penetrating injury to the head. The pathophysiological evolution of TBI involves complex biochemical and genetic changes. Common sequelae of TBI include seizures and psychiatric disorders, particularly depression. In considering pharmacologic interventions for treating post-TBI depression, it is important to remember that TBI patients have a higher risk of seizures; therefore, the benefits of prescribing medications that lower the seizure threshold need to be weighed against the risk of seizures...
April 1, 2018: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29707425/psychosis-in-a-child-with-atypical-autism-a-case-report-and-a-brief-review-of-the-association-of-psychosis-and-autism
#20
Swapnajeet Sahoo, Susanta Kumar Padhy, Neha Singla, Aakanksha Singh
Recent studies have shown that individuals with an autism spectrum disorder (ASD) are at an increased risk of developing psychosis. Diagnosing psychosis in such individuals can be challenging when they present with symptoms at a young age. A careful history and thorough assessment are essential for proper diagnosis to avoid mislabeling certain behavioral problems encountered among children with ASD. We present the case of a 12-year-old child with atypical autism who developed psychotic symptoms that led to a diagnostic dilemma...
April 1, 2018: Innovations in Clinical Neuroscience
journal
journal
43359
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"